Pidilizumab, also known by its developmental code name, is a monoclonal antibody that primarily targets the programmed cell death protein 1 (PD-1) receptor, which plays a crucial role in regulating immune responses. This substance is designed to enhance the immune system's ability to recognize and attack cancer cells by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Pidilizumab has been investigated for its potential therapeutic applications in various cancers, particularly in hematological malignancies. Its mechanism of action involves reactivating T-cells that have been inhibited by tumor cells, thereby promoting an anti-tumor immune response. The compound is typically administered via injection and is subject to rigorous clinical trials to evaluate its efficacy and safety profile. As with many monoclonal antibodies, potential side effects may include immune-related adverse events, which necessitate careful monitoring during treatment. Overall, pidilizumab represents a promising approach in the field of immuno-oncology, contributing to the development of targeted therapies for cancer treatment.

Pidilizumab

1036730-42-3: B932PAQ1BQ, Pidilizumab, MDV 9300, CT 011, Immunoglobulin G1, anti-(receptor PD-1 (Programmed Death 1)) (human-mouse monoclonal CT-011 γ1-chain), disulfide with human-mouse monoclonal CT-011 κ-chain, dimer

Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologic

Anti-DLL1 monoclonal antibody; potential for cancer and infectious disease treatment

CAS 1036730-42-3: Pidilizumab

Pidilizumab

Ref: TM-T81461

Pidilizumab

Ref: 3D-CLA1320